Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 50

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from zero to four months from the date of the transaction, and accordingly, there is no significant financing component.Performance ObligationsA performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 15

Disaggregated RevenueThe following table represents disaggregated net product sales in the periods presented as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Net product sales:   EXPAREL$142,917 $136,852 $279,446 $269,282    ZILRETTA31,334 30,707 54,672 56,546    iovera°5,588 5,674 10,711 10,704    Bupivacaine liposome injectable suspension508 3,154 3,112 5,679       Total net product sales$180,347 $176,387 $347,941 $342,211 

NOTE 5—INVENTORIES

The components of inventories, net are as follows (in thousands):June 30,December 31,20252024Raw materials$40